Search for: "Glaxo SmithKline"
Results 1 - 20 of 56
Sorted by Relevance | Sort by Date
20 Nov, 2008 3:53 pm
... her warning and tried to make her stop talking about it with other doctors and hospitals, according to documents and interviews. Glaxo
defends its effort, which it says was an attempt to correct "inaccuracies." The head of the doctor's hospital says he ignored Glaxo's ... said
he was characterized as a "liar" and threatened with a lawsuit if SmithKline's stock dropped because of his statements about Avandia's possible
dangers. Glaxo upgraded the warnings on Avandia's label more than a dozen times ...
15 Sep 11:02 am
... and Carol Louik to turn over other information about their contacts with the drugmaker. Some of that information relates to communications Glaxo had with the researchers as they prepared to submit the study to the New England Journal of Medicine for publication, according to ... in case 09-10198,
U.S. District Court, District of Massachusetts (Boston). The Philadelphia case is Kilker v. SmithKline Beecham Corp., 2007- 001813, Court of
Common Pleas, Philadelphia County, Pennsylvania. If you or a ...
8 Oct 12:27 am
... all U.S. Food and Drug Administration regulations in testing and monitoring Paxil, according to a former employee for the agency. Glaxo
reported to the FDA on a regular basis and supplied animal toxicology studies that didn't indicate the drug could cause ... didn't cause it, but we don't know the actual epidemiology of
what did cause it." The case is Kilker v. SmithKline Beecham Corp. dba GlaxoSmithKline, 2007-001813, Court of Common Pleas, Philadelphia
County, Pennsylvania (Philadelphia). If you ...
13 Oct 3:29 pm
... state court in Philadelphia deliberated about seven hours over two days before finding Glaxo failed to properly warn doctors and pregnant
users of Paxil's risk. ... child's heart defects. The Philadelphia Common Pleas Court panel also found that Glaxo's handling of the drug wasn't
"outrageous," meaning the family couldn't ... turned the gun on himself after taking Paxil. The Philadelphia case is Kilker v. SmithKline
Beecham Corp. dba GlaxoSmithKline, 2007-001813, Court of Common Pleas, Philadelphia ...
13 Oct 2:24 am
... caused birth defects, a lawyer said in closing arguments of a trial over the drug. Glaxo researchers never followed up on studies showing
Paxil posed a birth-defect risk ... defects and hid those risks to increase profits. The family of Lyam Kilker claims Glaxo withheld
information from consumers and regulators about Paxil's risks and failed ... her son's life-threatening heart defects. The case is Kilker v. SmithKline Beecham Corp. dba GlaxoSmithKline, 2007-001813, Court of Common Pleas, Philadelphia ...
22 Nov 9:39 pm
Tide turning against drug-pricing suits? Glaxo SmithKline beats back Kentucky case [Longstreth, AmLaw
Daily] Court in Australia deems litigation funding pact improper as "unregistered managed investment scheme" [New Lawyer] Should docs be careful what they ask for? Michelle Mello...
2 Sep 11:22 pm
... *2 (M.D. Tenn. Aug. 13, 2009) (Florida statute); White v. SmithKline Beecham Corp., 538 F. Supp.2d 1023, 1028-29 (W.D. ... -the-FDA
exceptions like Michigan's. Federal Vaccine Act: Sykes v. Glaxo-SmithKline, 484 F. Supp.2d 289, 305
n.16 (E.D. ... known defects from the FDA asserted as "parallel" claim in PMA device case); Mason v. Smithkline Beecham Corp., 546 F. Supp.2d
618, 627 n.5 (C ... 526 F.3d 203 (5th Cir. 2008). Stretching the limits, Knipe v. SmithKline Beecham, 583 F. Supp.2d 553 (E.D. Pa. 2008), ...
26 Aug 9:59 am
... to trim off an extra 5-10 pounds or so, just to fit Roche's vision of the chic woman. Xenical (Roche) is the 120 milligram per pill prescription predecessor of Alli (Glaxo Smithkline), which is the 60 milligram over the counter version of the generic compound, orlistat. Orlistat is
also known ... this only a partial list of side effects." Despite the side effects and the FDA's concern, Glaxo argues that since Alli is only
60 mg, it is safe if taken as directed, and The UK News ...
23 Sep, 2007 2:28 pm
... (Tex. Dist. Jan. 31, 2007) (finding preemption in a Prempro/heart attack case). 16. Sykes v. Glaxo-SmithKline, 484 F. Supp. 2d 289 (E.D. Pa. 2007) (finding preemption in a Thimerosal/vaccine/neurological injuries case; speaks to both vaccine preemption and
drug preemption generally). 17. Kelly ... . App. Aug. 28, 2007) (finding no preemption in an Orimune polio vaccine case). 35. Tucker v. SmithKline Beecham Corp., No. 04-01748-DFH-WTL, slip op. (S.D. Ind. Sept. 19, 2007) ...
18 Oct, 2007 7:27 am
... of congress supported it. See, 153 Cong. Rec. S11839-40 (discussing correctness of preemption holding in Dowhal v. SmithKline Beecham, 88
P.3d 1 (Cal. 2004), that plaintiffs could not pursue state law claims for manufacturer's failure to provide warnings determined by FDA to be scientifically unsubstantiated); id. at
11840 (endorsing approach to preemption taken in Sykes v. Glaxo-SmithKline, 484 F. Supp. 2d 289 (E.D.
Pa. 2007), - another case we like - ...
27 Dec, 2007 7:09 am
... the list over several other similar decisions because it's a state appellate court in a difficult jurisdiction for defendants. This decision is subject to further appeal. Our post
is here. 7. Sykes v. Glaxo-SmithKline, 484 F. Supp. 2d 289 (E.D. Pa. 2007). The best pro-preemption
... D. Fla. 2007) (learned intermediary rule applies to consumer fraud claims); (17) Tucker v. SmithKline Beecham Corp., 2007 WL 2726259 (S.D.
Ind. Sept. 19, 2007) (SSRI conflict ...
17 Apr, 2008 10:39 am
... Pa. Aug. 31, 2007) (drug labeling); Wright v. Henderson, 2007 WL 2484317, at *2 (N.D. Ga. Aug. 28, 2007) (FDA press release); Sykes v. Glaxo-SmithKline, 484 F. Supp.2d 289, 293, 295, 310 (E.D. Pa. 2007) (FDA talk paper; FDA vaccine approvals; FDA
guidances); Fellner v. Tri-Union Seafoods, ... stands in stark contrast to the court's refusal to even consider FDA amicus briefs in Collins v. Smithkline Beecham Corp., 2008 WL 744070 (Pa. C.P. Philadelphia Co. March 11, 2008), a case ...
25 Jul, 2006 7:16 am
... class of trade and, thereby, keeping pharmaceutical prices artificially high for consumers and substantially weakening the integrity and security of the Nation's Drug supply." The
named Defendants are: Alcon, AstraZeneca, Boehringer, Bristol-Myers Squibb, Eisai, Forest, Glaxo SmithKline, Kos, Merck, Novartis, Organon, Pfizer, Sanofi-Aventis, Schering-Plough, Takeda, Wyeth, McKesson, Cardinal, AmerisourceBergen, H.D. Smith, ...
14 Feb, 2007 6:58 am
... . He focuses on patent licensing and litigation in virtually every technology and in jurisdictions nationwide, including numerous district courts, the International Trade Commission
and the Federal Circuit. Frank Grassler, Vice President Intellectual Property/Biotechnology, Glaxo SmithKline, Research Triangle Park, NC. The panel will address these and other key questions: How have the courts and agencies applied ...
31 Mar, 2007 9:11 am
... , March 28. In 65 nicely reasoned pages, he came out in favor of both Vaccine Act and FDA prescription drug preemption. If that doesn't make your spine tingle . . . well, why are
you reading this blog, anyway? In Sykes v. Glaxo-SmithKline, et al., No. 06-1111, slip op. (E.D. Pa.
Mar. 28, 2007) (sorry -- we can't find it on the web, and we can't post it on a databus from where we're blogging, so we can't ...
5 Apr, 2007 5:39 am
... typically ignores regulatory practice, the regulation's requirement that any CBE warning changes be simultaneously submitted to the FDA, and that the FDA has ultimate authority to
approve or reject the labeling change. E.g., Sykes v. Glaxo-SmithKline, 2007 WL 957337, at *18 (E.D.
Pa. Mar. 28, 2007) ("A manufacturer may, under FDA regulations, strengthen a labeling warning, but in practice manufacturers typically consult with FDA before doing so to ...
17 May, 2007 9:09 am
... ) Barnhill states that only Colacicco has afforded deference to the FDA's position. Slip op. at 11. That's just plain wrong, and omits three other opinions, all of which deferred to
the FDA with significant reasoning. See Sykes v. Glaxo-SmithKline, 2007 WL 957337, at *19-23 (E.D.
Pa. March 28, 2007); In re Bextra & Celebrex Marketing Sales Practices & Product Liability Litigation, 2006 WL 2374742, at *6-9 ...
4 Jun, 2007 3:06 am
... beyond pro bono work… But I'll tease that out over time. Next, Marshall Goldsmith, executive coach extraordinaire to CEOs of companies such as Glaxo SmithKline, Ford, and many others, spoke about "feedforward" as opposed to feedback. Rather than focusing on
what's happened in the past - which is, by definition, unchangeable - Goldsmith recommends a forward-looking process in which the subject selects a behavior to change and ...
18 Jun, 2007 10:09 pm
Unsolicited email is beginning to arrive in people's inboxes soliciting clients to sue over the Glaxo SmithKline diabetes drug, Avandia. Bill Childs has more, as does Eric Turkewitz, who observes that no law firm is named in the ad, and proposes a course of
action: Figuring out which law firms have hired the spammer should be easy for an enterprising citizen-journalist, simply by filling out the ...
26 Jul, 2007 11:18 am
... -16, 1986 U.S.C.C.A.N. 6344, 6366-67. You can't get much more explicit than that. Prior to Ferrari, every court that had considered Vaccine Act preemption had found non-comment-k
claims preempted. Sykes v. Glaxo-SmithKline, 484 F. Supp.2d 289, 299-302 (E.D. Pa. 2007); Blackmon v.
American Home Products Corp., 328 F.Supp.2d 659, 663-66 (S.D. Tex. 2004); Militrano v. Lederle Laboratories, 769 N.Y. ...
Search on: Blawgs.FM | BlawgSearch Google Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!